Colombian decree will allow 'non-comparable' biologics, say R&D firms
This article was originally published in SRA
Executive Summary
The publication of a Colombian decree on the evaluation of biotechnological medicines has caused something of a stir, not least because it offers three separate approval pathways, one of which R&D-based companies say will allow the approval of 'non-comparable' versions of originator biologic medicines1.
You may also be interested in...
Poor Biosimilarity Practices, Impurities and New Technologies Debated At European Pharmacopoeia Event
Some regulators are wrongly using monographs rather than a biosimilarity exercise to show comparability of a biosimilar with its reference product, it was suggested at the European Pharmacopoiea’s latest conference. Also discussed were issues such as how to align the PhEur with the new ICH guideline on elemental impurities, and how advances in technology are being dealt with.
Poor Biosimilarity Practices, Impurities and New Technologies Debated At European Pharmacopoeia Event
Some regulators are wrongly using monographs rather than a biosimilarity exercise to show comparability of a biosimilar with its reference product, it was suggested at the European Pharmacopoiea’s latest conference. Also discussed were issues such as how to align the PhEur with the new ICH guideline on elemental impurities, and how advances in technology are being dealt with.
COVID-19 Vaccine Contracts Rarely Disclose Price & Delivery Details
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: